InvestSMART

Imugene Limited (ASX: IMU) - Announcements

Current share price for IMU : $0.035 0.003 (7.89%)+

ASX company news and announcements for Imugene Limited (IMU) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Imugene Limited (IMU) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Imugene Limited (IMU), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Imugene Limited (IMU)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$19 Letter to IMUOA Option Share Holders 7 Aug 2020 10:30AM $0.056 $0.035 fallen by 37.50%
$19 Imugene Receives Clinical Guidance from US FDA for Vaxinia 6 Aug 2020 8:49AM $0.056 $0.035 fallen by 37.50%
$19 Change of Director's Interest Notice - LC 5 Aug 2020 12:44PM $0.053 $0.035 fallen by 33.96%
$19 CEO and Managing Director increases shareholding in Imugene 5 Aug 2020 12:40PM $0.052 $0.035 fallen by 32.69%
$19 Appendix 2A and 708A Notice 5 Aug 2020 11:25AM $0.053 $0.035 fallen by 33.96%
$19 Proposed issue of Securities - IMU 4 Aug 2020 3:38PM $0.056 $0.035 fallen by 37.50%
$19 Appendix 4C - quarterly 27 Jul 2020 10:54AM $0.054 $0.035 fallen by 35.19%
$19 Imugene Receives Second PD1-VAXX Ethics Trial Approval 17 Jul 2020 9:13AM $0.036 $0.035 fallen by 2.78%
$19 Imugene Receives Ethics Approval to Start PD1-VAXX Trial 14 Jul 2020 9:14AM $0.034 $0.035 risen by 2.94%
$19 New mimotope cancer vaccine results published 28 May 2020 12:22PM $0.034 $0.035 risen by 2.94%
$19 Release of Securities from Escrow 15 May 2020 4:46PM $0.030 $0.035 risen by 16.67%
$19 Imugene HER-Vaxx Phase 2 Clinical Update 4 May 2020 9:08AM $0.026 $0.035 risen by 34.62%
$19 IMU Presents Vaxinia Clinical Plan at AACR Annual Meeting 27 Apr 2020 2:08PM $0.024 $0.035 risen by 48.94%
$19 IMU Presents PD1-Vaxx Clinical Plan at AACR Annual Meeting 27 Apr 2020 2:08PM $0.024 $0.035 risen by 48.94%
$19 Appendix 4C - quarterly 24 Apr 2020 12:35PM $0.023 $0.035 risen by 52.17%
$19 Change of Director's Interest Notice - LR 30 Mar 2020 10:47AM $0.019 $0.035 risen by 84.21%
$19 Change of Director's Interest Notice - CW 25 Mar 2020 11:36AM $0.018 $0.035 risen by 94.44%
$19 Change of Director's Interest Notice - CW 18 Mar 2020 9:20AM $0.018 $0.035 risen by 94.44%
$19 Change of Director's Interest Notice - LC 17 Mar 2020 9:34AM $0.016 $0.035 risen by 118.75%
$19 Change of Director's Interest Notice - LC 13 Mar 2020 10:07AM $0.017 $0.035 risen by 105.88%
$19 Change of Director's Interest Notice - CW 11 Mar 2020 11:14AM $0.023 $0.035 risen by 52.17%
$19 Half Yearly Report and Accounts 26 Feb 2020 6:47PM $0.026 $0.035 risen by 34.62%
$19 Ceasing to be a substantial holder 13 Feb 2020 5:25PM $0.034 $0.035 risen by 2.94%
$19 Appendix 4C - quarterly 31 Jan 2020 10:05AM $0.034 $0.035 risen by 2.94%
$19 Imugene PD1-Vaxx Immunotherapy Update 28 Jan 2020 9:17AM $0.034 $0.035 risen by 2.94%

726 - 750 of 1209 results

Page 30 of 49

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.